New data on Crohn’s disease presented at Digestive Disease Week in Chicago
New studies show that patients with moderate to severe Crohn’s diseaseA chronic inflammatory disease affecting the gastrointestinal tract. can maintain remissionThe lessening or disappearance of the symptoms or signs of a disease. through three years of therapy with adalimumab (HUMIRA®). It appears that not only has adalimumab demonstrated its efficacy at the beginning of the treatment but it has also shown to maintain its effectiveness over the long-term - pretty important when considering how to manage a chronicA disease of long duration generally involving slow changes. condition like Crohn’s disease.
A secondary analysis of the same study demonstrated that patients being treated with adalimumab for Crohn's disease may also be able to achieve long-term steroid-free remission.


